Table 3 Coeliac disease‐specific antibodies and autoantibodies in coeliac patients diagnosed in childhood and maintained on a normal diet until adulthood (no. positive/no. tested (% of positive).
| Total cohort (n = 61) | Latent (n = 13) | Silent (n = 48) | p Value latent vs silent | |
|---|---|---|---|---|
| IgA anti‐gliadin | 25/54 (46%) | 0/12 (0%) | 25/42 (60%) | <0.0002 |
| IgA anti‐endomysium | 41/56 (79%) | 4/12 (33%) | 37/44 (84%) | <0.001 |
| IgA anti‐tissue transglutaminase | 21/31 (68%) | 4/9 (44%) | 17/22 (77%) | <0.05 |
| At least one antibody positive | 46/56 (82%) | 5/12 (42%) | 41/44 (93%) | <0.0003 |
| Anti‐nuclear | 5/54 (11%) | 1/13 (8%) | 5/42 (12%) | NS |
| Anti‐smooth muscles | 3/55 (5%) | 0/13 (0%) | 3/42 (7%) | NS |
| Anti‐thyroglobulin | 3/55 (5%) | 0/13 (0%) | 3/42 (7%) | NS |
| Anti‐thyroperoxidase | 3/55 (5%) | 0/13 (0%) | 3/42 (7%) | NS |
| Anti‐LKM1 | 0/55 (0%) | 0/13 (0%) | 0/42 (0%) | NS |
| Anti‐LC1 | 0/55 (0%) | 0/13 (0%) | 0/42 (0%) | NS |
| Patients with at least one autoantibody | 8/55 (14.5%) | 1/13 (8%) | 7/42 (17%) | NS |
Latent, patients with no atrophy; silent, patients with villous atrophy.
NS, non‐significant.